China’s BSN Onboards EY for Ethereum Compliance Tools

China’s BSN Onboards EY for Ethereum Compliance Tools

TipRanks

Let’s talk about risk and the big picture. It’s an appropriate time, as the big risk – presented by the COVID-19 pandemic – is finally receding thanks to the ongoing vaccination program. COVID is leaving behind an economy that was forced into shutdown one year ago while in the midst of a great expansion, boosted by the deregulation policies. While the new Biden Administration is busy reversing many Trump policies, at least for now the economy is rebounding. And this brings us to risk. A time of economic growth and rebound is a forgiving time to move toward risk investments, as general economic growth tends to lift everything. Two strategists from JPMorgan have recently chimed in, promoting the view that the market’s fundamentals are still sound, and that small- to mid-cap sector is going to keep rising. First, on the general conditions, quant strategist Dubravko Lakos-Bujas wrote, “Although the recent technical selloff and short squeeze is receiving a lot of attention, we believe the positive macro setup, improving fundamentals and COVID-19 outlook, strength of the US consumer, as well as the reflation theme remain the bigger forces at play. Not only should this drive further equity upside, but it remains favorable for continued rotation into economic reopening…” Building on this, Eduardo Lecubarr, chief of the Small/Mid-Cap Strategy team, sees opportunity for investors now, especially in the smaller value stocks. “We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain… Many macro indicators did fall in January but SMid-Caps and equities in general continued to edge higher,” Lecubarr noted. And if you are prone to look at high-risk, small- to mid-cap stocks, you’ll find yourself drawn to penny stocks. The risk involved with these plays scares off the faint hearted as very real problems like weak fundamentals or overwhelming headwinds could be masked by the low share prices. So, how should investors approach a potential penny stock investment? By taking a cue from the analyst community. These experts bring in-depth knowledge of the industries they cover and substantial experience to the table. Bearing this in mind, we used TipRanks’ database to find two compelling penny stocks, according to Wall Street analysts. Both tickers boast a Strong Buy consensus rating and could climb over 200% higher in the year ahead. CNS Pharmaceuticals (CNSP) We will start with CNS Pharmaceuticals, a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNS’s flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a ‘Durable Complete Response,’ defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the company’s asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brookline’s 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. “Until now, the inability of anthracyclines to cross the blood brain barrier prevented its use for treatment of brain cancers. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors… Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032,” Raja opined. “CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021… In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity,” the analyst added. To this end, Raja rates CNSP a Buy, and his $10 price target implies room for a stunning 350% upside potential in the next 12 months. (To watch Raja’s track record, click here) What does the rest of the Street have to say? 3 Buys and 1 Hold add up to a Strong Buy consensus rating. Given the $8.33 average price target, shares could climb ~275% in the year ahead. (See CNSP stock analysis on TipRanks) aTyr Pharma (LIFE) The next stock we’re looking at, aTyr Pharma, has a focus on inflammatory disease. Its leading drug candidate, ATYR1923, is a Neuropilin-2 (NRP2) agonist, working through the receptor proteins expressed by the NRP2 gene. These pathways are important for cardiovascular development and disease, and play a role in the inflammatory lung disease pulmonary sarcoidosis. In December, the company reported that the drug candidate had completed enrollment of 36 patients in a Phase 1b/2a clinical trial, testing the drug in the treatment of pulmonary sarcoidosis. Results of the current study are expected in 3Q21, and will inform further trials of ATYR1923, including against other forms of inflammatory lung disease. On a more immediate note, in early January the company announced top-line results of another Phase 2 clinical involving ATRY1923 – this time in the treatment of patients hospitalized with severe respiratory complications from COVID-19. The results were positive, showing that a single dose of ATYR1923 (at 3 mg/kg) resulted in a 5.5-day median recovery time. Overall, of the patients dosed in this manner, 83% saw recovery in less than one week. Covering LIFE for Roth Capital, 5-star analyst Zegbeh Jallah noted, “We like the risk profile here, with two shots on goal, and updated data details from the COVID study is expected in the coming months. Also announced recently, is that data from aTyr’s Pulmonary Sarcoidosis program, will be reported in 3Q21… the success of either of these studies could result in a doubling or more of the market cap as these opportunities appear to barely be accounted for by investors.” In line with his optimistic approach, Jallah gives LIFE shares a Buy rating and his $15 price target suggests an impressive 277% potential upside for the coming year. (To watch Jallah’s track record, click here) Other analysts are on the same page. With 2 additional Buy ratings, the word on the Street is that LIFE is a Strong Buy. On top of this, the average price target is $13.33, suggesting robust growth of ~236% from the current price of $3.97. (See LIFE stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Ethereum, Litecoin, and Ripple’s XRP – Daily Tech Analysis – February 6th, 2021

Ethereum

Ethereum rallied by 7.75% on Friday. Reversing a 4.26% slide from Thursday, Ethereum ended the day at $1,721.06.

It was a mixed start to the day. Ethereum fell to an early morning intraday low $1,589.17 before making a move.

Steering clear of the first major support level at $1,536, Ethereum rallied to a late afternoon intraday high and a new swing hi $1,763.93.

Ethereum broke through the first major resistance level at $1,679 and the second major resistance level at $1,761.

A late pullback saw Ethereum fall back through the second major resistance level to $1,680 levels before wrapping up the day at $1,721 levels.

At the time of writing, Ethereum was up by 0.53% to $1,730.23. A mixed start to the day saw Ethereum fall to an early morning low $1,720.01 before rising to a high $1,739.60.

Ethereum left the major support and resistance levels untested early on.

For the day ahead

Ethereum would need to avoid a fall through the pivot level at $1,691 to support a run at the first major resistance level at $1,794.

Support from the broader market would be needed, however, for Ethereum to break out from Friday’s swing high $1,763.93.

Barring an extended crypto rally, the first major resistance level and resistance at $1,800 would likely cap any upside.

In the event of an extended crypto rally, Ethereum could test resistance at $1,950 before any pullback. The second major resistance level sits at $1,866.

Failure to avoid a fall through the $1,691 pivot would bring the first major support level at $1,619 into play.

Barring an extended sell-off, however, Ethereum should steer clear of sub-$1,600 levels. The second major support level sits at $1,517.

Looking at the Technical Indicators

First Major Support Level: $1,619

Pivot Level: $1,691

First Major Resistance Level: $1,794

23.6% FIB Retracement Level: $1,367

38.2% FIB Retracement Level: $1,121

62% FIB Retracement Level: $724

Litecoin

Litecoin rallied by 6.82% on Friday. Partially reversing a 7.06% slide from Thursday, Litecoin ended the day at $155.15.

Story continues

It was also a mixed start to the day. Litecoin fell to an early morning intraday low $143.63 before making a move.

Steering clear of the first major support level at $137.96, Litecoin rallied to an early afternoon intraday high $156.99.

Litecoin broke through the 23.6% FIB of $148 and the first major resistance level at $155.79 before hitting reverse.

The reversal saw Litecoin fall back to sub-$150 levels before closing out the day at $155 levels.

While failing to break back through the first major resistance level, the 23.6% FIB limited the downside late on.

At the time of writing, Litecoin was up by 0.29% to $155.60. A mixed start to the day saw Litecoin fall to an early morning low $154.91 before striking a high $156.00.

Litecoin left the major support and resistance levels untested early on.

For the day ahead

Litecoin would need to avoid a fall through the $151.92 pivot level to support a run at the first major resistance level at $160.22.

Support from the broader market would be needed, however, for Litecoin to break out from Friday’s high $156.99.

Barring an extended crypto rally, the first major resistance level would likely cap any upside.

In the event of an extended breakout, Litecoin could test resistance at $170 before any pullback. The second major resistance level sits at $165.28.

Failure to avoid a fall through the $151.92 pivot level would bring the 23.6% FIB of $148 and the first major support level at $146.86 into play.

Barring an extended sell-off, Litecoin should steer clear of sub-$140 levels. The second major support level sits at $138.56.

Looking at the Technical Indicators

First Major Support Level: $146.86

Pivot Level: $151.92

First Major Resistance Level: $160.22

23.6% FIB Retracement Level: $148

38.2% FIB Retracement Level: $125

62% FIB Retracement Level: $87

Ripple’s XRP

Ripple’s XRP rose by 1.49% on Friday. Following a 12.12% jump on Thursday, Ripple’s XRP ended the day at $0.45276.

A bullish start to the day saw Ripple’s XRP rise to an early morning intraday high $0.47230 before hitting reverse.

Falling short of the first major resistance level at $0.4917, Ripple’s XRP slid to a late morning intraday low $0.42657.

Steering well clear of the 38.2% FIB of $0.4070 and the first major support level at $0.3905, Ripple’s XRP revisited $0.46 levels before easing back.

At the time of writing, Ripple’s XRP was down by 0.01% to $0.45273. A mixed start to the day saw Ripple’s XRP rise to an early morning high $0.45688 before falling to a low $0.44863.

Ripple’s XRP left the major support and resistance levels untested early on.

For the day ahead

Ripple’s XRP will need to avoid a fall back through the $0.4505 pivot level to bring the first major resistance level at $0.4745 into play.

Support from the broader market would be needed, however, for Ripple’s XRP to break back through to $0.47 levels.

Barring another extended crypto rally, the first major resistance level and Friday’s high $0.4723 would likely cap any upside.

In the event of an extended rally, Ripple’s XRP could the second major resistance level at $0.4963 and resistance at $0.50.

Failure to avoid a fall back through the $0.4505 pivot would bring the first major resistance level at $0.4288 into play.

Barring an extended sell-off, Ripple’s XRP should steer clear of sub-$0.40 levels. The 38.2% FIB of $0.4070 and the second major support level at $0.4048 should limit the downside.

Looking at the Technical Indicators

First Major Support Level: $0.4288

Pivot Level: $0.4505

First Major Resistance Level: $0.4745

23.6% FIB Retracement Level: $0.6274

38.2% FIB Retracement Level: $0.5285

62% FIB Retracement Level: $0.3687

Please let us know what you think in the comments below.

Thanks, Bob

This article was originally posted on FX Empire

More From FXEMPIRE:

Ethereum catapults to new all-time high past $1,600 as investors pile in ahead of next week’s launch of CME futures

Ethereum shot past $1,600 to secure a new all-time high ahead of next week’s CME futures launch.

The digital asset hit a record high of $1,698.56. Meanwhile, bitcoin rose 3%, to $37,381.

Crypto traders have a valuable lesson to learn from last week’s Reddit war against Wall Street players.

Sign up here for our daily newsletter, 10 Things Before the Opening Bell.

Ether, the native cryptocurrency of the Ethereum network, pierced a new all-time high on Thursday, bringing its year-to-date rally to 128%.

Continuing bullish momentum led the token’s price to hit a record high of $1,698.56, before settling around 2% lower.

Although the trade seems to be partly fueled by speculation, a major factor driving demand is the Chicago Mercantile Exchange’s launch of Ethereum futures on February 8.

Ethereum’s upward trajectory may be representative of the “fortunes of the entire cryptocurrency ecosystem,” said Paolo Ardoino, CTO of Bitfinex. One macroeconomist expects the price to surge higher, to around $1,920, ahead of the CME launch.

Rising confidence among institutional investors over blockchain-based technologies has also helped Ethereum’s influence grow within the sphere of cryptocurrencies. Euphoria in the hot asset class boosted the total market value of cryptocurrencies above $1 trillion for the first time last month.

Grayscale Investments, the world’s largest cryptocurrency fund manager, this week added an extra 25,000 ETH coins, bringing its total Ethereum holdings to $4.5 billion. The fund also reopened its Ethereum fund to accredited investors.

Read More: Famed short-seller Carson Block says a new type of liquidity bubble is feeding the wild swings in day-trading favorites like GameStop - and warns that stocks have become a fragile ‘game’

Separately, bitcoin rose 3% on Thursday to $37,381.04, against the backdrop of continuing global macroeconomic uncertainty with the potential to devalue fiat currencies.

Further, crypto traders have a valuable lesson to learn from the tussle between Reddit traders and big Wall Street players last week.

“When you engage with centralized finance, you will always be, to some extent, putting your trust and faith in a brand,” said Sergey Nazarov, the co-founder of Chainlink. Decentralized finance offers users the ability to trade without the fear of being shut down, rules that apply equally to all sides, and full control over one’s assets, he said.

“Add in the fact that we’re entering one of the lowest yield environments in decades and DeFi lets anyone earn high yield, and of course more and more people will pour into the Ethereum space in order to engage with these popular applications,” Nazarov said.

Read more: Investors are flocking to trade Dogecoin and other hot digital tokens with no Robinhood-style restrictions on Voyager. The CEO tells us why Bitcoin will hit $100,000 this year - and 3 other cryptocurrencies to watch